GH Research (GHRS) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Omeros (OMER) has outperformed GH Research (GHRS) over the past year, gaining 335.5% versus a gain of 55.3%. Over five years, OMER leads with a +147.3% price change compared with +20.3% for GHRS. GH Research is the larger company by market cap ($1.40 billion vs $1.38 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | OMER |
|---|---|---|
| Share price | $20.45 | $19.12 |
| Market cap | $1.40B | $1.38B |
| 1-day change | -2.90% | +1.97% |
| YTD return | +61.02% | +11.29% |
| 1-year return | +55.28% | +335.54% |
| 5-year return | +20.29% | +147.35% |
| P/E ratio (TTM) | — | 15.67 |
| Forward P/E | — | 15.54 |
| EPS (TTM) | $-0.99 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.44 | $21.24 |
| 52-week low | $12.04 | $4.06 |
| Distance from 52-week high | -34.95% | -9.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.73% | +43.83% |
| Average volume | 294.29K | 1.74M |
| Shares outstanding | 68.64M | 72.39M |
| Employees | 73 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed GHRS by 280.3 percentage points over the past year.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
GHRS vs OMER FAQ
Which is bigger, GH Research or Omeros?
GH Research (GHRS) is larger, with a market capitalization of $1.40B compared with $1.38B for Omeros (OMER).
Which stock has performed better over the past year, GHRS or OMER?
OMER returned +335.54% over the past 12 months, compared with +55.28% for GHRS (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.